Sales rose 27% in Q3 2024, driven by strong growth in Denmark and cost control, while a SEK 4.9m rights issue bolstered expansion efforts. The planned Med Things AS acquisition was canceled, and the company remains focused on Nordic market growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.